{"title":"Comprehensive risk stratification for adult T-cell lymphoblastic lymphoma undergoing allogeneic haematopoietic stem cell transplantation.","authors":"Fangfang Yu, Xiaolin Yu, Xiaoxia Hu, Erlie Jiang, Jian Zhou, Ying Lu, Xiaoyu Zhu, Jiangbo Wan, Kourong Miao, Yuewen Fu, Jiahua Niu, Liping Wan, Fang Zhou, Xianmin Song","doi":"10.1111/bjh.70102","DOIUrl":null,"url":null,"abstract":"<p><p>Relapse remains the primary cause of transplant failure in T-cell lymphoblastic lymphoma (T-LBL) after allogeneic haematopoietic stem cell transplantation (allo-HSCT), yet prognostic data are scarce. We conducted a multicentre retrospective study of 104 adult T-LBL patients in complete metabolic remission (CMR) undergoing allo-HSCT. Pretransplant Deauville score (DS) was evaluated, and a risk model integrating DS, immunophenotype and donor type was developed. Patients with DS of 3 had significantly inferior 2-year overall survival (OS) (70.5% vs. 77.4% vs. 86.8%, p < 0.001), progression-free survival (PFS) (51.5% vs. 73.0% vs. 81.1%, p < 0.001) and higher relapse rates (42.1% vs. 15.4% vs. 9.8%, p < 0.001) compared to DS of 1-2. Multivariable analysis identified pretransplant DS, immunophenotype and donor type as independent risk factors for post-transplant relapse. These variables were integrated to construct a novel risk model stratifying patients into low- (66.0%), intermediate- (21.3%) and high-risk (12.7%) groups, strongly discriminating OS (p < 0.001), PFS (p < 0.001) and relapse (p < 0.001), with a C-index of 0.706. Internal validation confirmed that the risk stratification model had good discrimination, calibration and clinical benefit. Our findings propose a clinically actionable tool to identify high-risk T-LBL patients for tailored post-transplant strategies.</p>","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":" ","pages":""},"PeriodicalIF":3.8000,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"British Journal of Haematology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/bjh.70102","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Relapse remains the primary cause of transplant failure in T-cell lymphoblastic lymphoma (T-LBL) after allogeneic haematopoietic stem cell transplantation (allo-HSCT), yet prognostic data are scarce. We conducted a multicentre retrospective study of 104 adult T-LBL patients in complete metabolic remission (CMR) undergoing allo-HSCT. Pretransplant Deauville score (DS) was evaluated, and a risk model integrating DS, immunophenotype and donor type was developed. Patients with DS of 3 had significantly inferior 2-year overall survival (OS) (70.5% vs. 77.4% vs. 86.8%, p < 0.001), progression-free survival (PFS) (51.5% vs. 73.0% vs. 81.1%, p < 0.001) and higher relapse rates (42.1% vs. 15.4% vs. 9.8%, p < 0.001) compared to DS of 1-2. Multivariable analysis identified pretransplant DS, immunophenotype and donor type as independent risk factors for post-transplant relapse. These variables were integrated to construct a novel risk model stratifying patients into low- (66.0%), intermediate- (21.3%) and high-risk (12.7%) groups, strongly discriminating OS (p < 0.001), PFS (p < 0.001) and relapse (p < 0.001), with a C-index of 0.706. Internal validation confirmed that the risk stratification model had good discrimination, calibration and clinical benefit. Our findings propose a clinically actionable tool to identify high-risk T-LBL patients for tailored post-transplant strategies.
复发仍然是同种异体造血干细胞移植后t细胞淋巴母细胞淋巴瘤(T-LBL)移植失败的主要原因,但预后数据很少。我们对104例完全代谢缓解(CMR)的成人T-LBL患者进行了一项多中心回顾性研究。评估移植前多维尔评分(Deauville score, DS),建立DS、免疫表型和供体类型相结合的风险模型。DS为3的患者的2年总生存率(OS)明显较低(70.5% vs. 77.4% vs. 86.8%, p
期刊介绍:
The British Journal of Haematology publishes original research papers in clinical, laboratory and experimental haematology. The Journal also features annotations, reviews, short reports, images in haematology and Letters to the Editor.